Can-Fite BioPharma (CANF) Competitors $1.52 +0.09 (+6.62%) (As of 05:45 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsTrends CANF vs. ATHA, TENX, AFMD, SNTI, BFRG, PIRS, CYTH, INAB, CLDI, and NRXPShould you be buying Can-Fite BioPharma stock or one of its competitors? The main competitors of Can-Fite BioPharma include Athira Pharma (ATHA), Tenax Therapeutics (TENX), Affimed (AFMD), Senti Biosciences (SNTI), Bullfrog AI (BFRG), Pieris Pharmaceuticals (PIRS), Cyclo Therapeutics (CYTH), IN8bio (INAB), Calidi Biotherapeutics (CLDI), and NRx Pharmaceuticals (NRXP). These companies are all part of the "pharmaceutical products" industry. Can-Fite BioPharma vs. Athira Pharma Tenax Therapeutics Affimed Senti Biosciences Bullfrog AI Pieris Pharmaceuticals Cyclo Therapeutics IN8bio Calidi Biotherapeutics NRx Pharmaceuticals Athira Pharma (NASDAQ:ATHA) and Can-Fite BioPharma (NYSE:CANF) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their community ranking, risk, valuation, analyst recommendations, institutional ownership, profitability, media sentiment, dividends and earnings. Do institutionals and insiders believe in ATHA or CANF? 57.1% of Athira Pharma shares are owned by institutional investors. Comparatively, 21.0% of Can-Fite BioPharma shares are owned by institutional investors. 19.8% of Athira Pharma shares are owned by insiders. Comparatively, 0.8% of Can-Fite BioPharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is ATHA or CANF more profitable? Can-Fite BioPharma's return on equity of 0.00% beat Athira Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Athira PharmaN/A -115.62% -88.94% Can-Fite BioPharma N/A N/A N/A Do analysts rate ATHA or CANF? Athira Pharma presently has a consensus price target of $13.83, suggesting a potential upside of 2,468.86%. Can-Fite BioPharma has a consensus price target of $14.00, suggesting a potential upside of 818.21%. Given Athira Pharma's higher possible upside, research analysts plainly believe Athira Pharma is more favorable than Can-Fite BioPharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Athira Pharma 0 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Can-Fite BioPharma 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Does the MarketBeat Community prefer ATHA or CANF? Athira Pharma received 15 more outperform votes than Can-Fite BioPharma when rated by MarketBeat users. Likewise, 54.05% of users gave Athira Pharma an outperform vote while only 8.06% of users gave Can-Fite BioPharma an outperform vote. CompanyUnderperformOutperformAthira PharmaOutperform Votes2054.05% Underperform Votes1745.95% Can-Fite BioPharmaOutperform Votes58.06%Underperform Votes5791.94% Which has more risk and volatility, ATHA or CANF? Athira Pharma has a beta of 2.99, meaning that its stock price is 199% more volatile than the S&P 500. Comparatively, Can-Fite BioPharma has a beta of 1.32, meaning that its stock price is 32% more volatile than the S&P 500. Which has stronger earnings & valuation, ATHA or CANF? Can-Fite BioPharma has higher revenue and earnings than Athira Pharma. Can-Fite BioPharma is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAthira PharmaN/AN/A-$117.67M-$2.85-0.19Can-Fite BioPharma$667K8.09-$7.63M-$1.79-0.85 Does the media refer more to ATHA or CANF? In the previous week, Athira Pharma had 3 more articles in the media than Can-Fite BioPharma. MarketBeat recorded 3 mentions for Athira Pharma and 0 mentions for Can-Fite BioPharma. Athira Pharma's average media sentiment score of 1.89 beat Can-Fite BioPharma's score of 0.00 indicating that Athira Pharma is being referred to more favorably in the media. Company Overall Sentiment Athira Pharma Very Positive Can-Fite BioPharma Neutral SummaryAthira Pharma beats Can-Fite BioPharma on 9 of the 17 factors compared between the two stocks. Ad Brownstone ResearchMan Who Called Nvidia Says: “Your Retirement Is Inside This Building.”In 2016, Jeff Brown called Nvidia at a split-adjusted 66 cents. The company just became the world's third $3 trillion company... And the stock is up massively since Jeff's recommendation. Now, Jeff has found five under-the-radar stocks which could power your retirement. Get Can-Fite BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CANF and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CANF vs. The Competition Export to ExcelMetricCan-Fite BioPharmaPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$5.40M$6.68B$5.24B$19.42BDividend YieldN/A2.98%5.11%3.65%P/E Ratio-0.8510.6887.6141.58Price / Sales8.09209.011,161.9618.76Price / CashN/A57.1543.3721.27Price / Book0.875.254.905.38Net Income-$7.63M$150.75M$120.44M$991.22M7 Day Performance5.88%5.56%3.94%2.92%1 Month Performance-25.62%-1.92%18.94%-3.44%1 Year Performance-28.75%9.74%29.71%12.23% Can-Fite BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CANFCan-Fite BioPharma1.9653 of 5 stars$1.52+6.6%$14.00+818.2%-31.9%$5.40M$667,000.00-0.858ATHAAthira Pharma3.4471 of 5 stars$0.52-10.5%$13.83+2,584.5%-74.9%$19.93MN/A-0.1840Short Interest ↓Positive NewsTENXTenax Therapeutics1.3269 of 5 stars$5.60-0.2%$16.00+185.7%-77.1%$19.09MN/A0.009Short Interest ↑AFMDAffimed4.2097 of 5 stars$1.17-1.6%$13.50+1,052.8%-72.3%$18.86M$877,000.000.0076Short Interest ↑Analyst RevisionSNTISenti Biosciences2.8396 of 5 stars$4.02+1.3%$10.00+148.8%-19.8%$18.45M$2.56M-0.264Short Interest ↑BFRGBullfrog AI0.5785 of 5 stars$2.08-0.5%N/A-21.9%$18.12M$60,000.00-2.454PIRSPieris Pharmaceuticals1.4273 of 5 stars$13.60-15.7%N/A+7.9%$17.95M$42.81M-1.12140Analyst ForecastNews CoverageGap DownCYTHCyclo Therapeutics2.8895 of 5 stars$0.62-2.4%$0.95+54.5%-68.3%$17.69M$870,725.00-0.689Short Interest ↑News CoverageGap DownINABIN8bio2.6499 of 5 stars$0.24-2.2%$7.75+3,085.4%-81.1%$17.64MN/A-0.3220Short Interest ↑Negative NewsGap UpCLDICalidi Biotherapeutics2.3154 of 5 stars$1.34-1.5%$16.67+1,143.8%N/A$17.53M$50,000.000.0041News CoverageGap DownNRXPNRx Pharmaceuticals2.99 of 5 stars$1.44-4.0%$32.00+2,122.2%-96.5%$17.42MN/A-0.672News CoverageGap Up Related Companies and Tools Related Companies Athira Pharma Alternatives Tenax Therapeutics Alternatives Affimed Alternatives Senti Biosciences Alternatives Bullfrog AI Alternatives Pieris Pharmaceuticals Alternatives Cyclo Therapeutics Alternatives IN8bio Alternatives Calidi Biotherapeutics Alternatives NRx Pharmaceuticals Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:CANF) was last updated on 12/26/2024 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredThe #1 Coin for November 2024Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this ...Crypto 101 Media | Sponsored“AI Killer” 10x More Powerful Than ChatGPTElon Musk may be about to “kill” the world’s most powerful AI. Very few people are talking about the one AI...Paradigm Press | SponsoredIs Jeff Bezos Crowning the Next Nvidia?It doesn't matter what you think about AI... Because Jeff Bezos's massive load-up on one tiny tech company ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Can-Fite BioPharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Can-Fite BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
